Member Info for Chelsea11

Redmile / Vulpes are not considered investors / partners of scale?

Holy Cardboard!

Blue diamond shaped :-0

Not 100% on this and happy to be corrected but this Congress would appear different to the likes of ASCO, in as much as there is no requirement for a Poster / Abstract submission in advance.

Does it follow then, that the presentation material can / will be as last minute as possible (allowing of course for prep time) and that maybe there are some new RNS implications around that? Would fit with a Q4 update.

Thinking out loud here, so kept that in mind please!

The recent rise in the SP, is making a mockery of the blizzard of negative posts made by some here, in the wake of the RNS Business Pipeline update in July.

Well done to all those who didn’t listen.

Well then TF, that must mean you’re giving the likes of Berm, Burble & Co no more than 60 secs after the Posters are uploaded, to comment on them here lol.

Come on. It’s very clear the precise timing is small beans.

The precise timing of uploading the Posters is small beans. That will happen.

What we haven’t yet seen though and in connection with the Milan Conference, is the deal progress updates promised within the infamous 10/07 Business Pipeline Update.

“ Scancell has developed a novel technology platform for producing monoclonal antibodies that recognise glycans with high specificity and affinity. The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company. Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company. These results along with updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023.”

I wonder if we might see a separate RNS for those elements, this week, or next.

TF - doesn’t say “immediately after” and was the weekend :-)

Thanks Ivy - helpful.

My professor always used to say to me, that I was average.

I thought that was Mean.

I’m still very dubious that SCOV will ever compete with currently approved COVID vaccines / makers. Also assume they too would be able to switch to needle-free at some future point, if desired. Just my opinion and I may be proven wrong.

The real value of that workstream imo, was the validation of the Company’s Immunobody & Avidimab platforms ie. a DNA vaccine, on steroids with Avidimab :-), resulted in T cell and antibody responses, without any safety issues. Then there is the learning and knowledge gained more broadly from the trial, relating to the platforms.

If one of the science types on here wants to apply some polish to my crude explanation of where the likely benefit of the trial would be, I really don’t mind :-)

HAGW

Thanks for your analysis Hasiba.

Clearly you know far more than experienced analysts working in the Bio sector.

Thanks EE. The Case Study for Immunocore on there is interesting and perhaps has some parallels.

https://consilium-comms.com/our-expertise/case-studies/immunocore/

(NB. Not a cross-ramp as not invested in Immunocore)

Oogle - “we will find out soon enough is the strategy is working”. Again, fully agree with you as that’s an echo of what I said about waiting for December Results (and AGM Statement now in) to feed the debate ie. facts reported by the Company and not someone’s totally blinkered view.

FTSE - “deliberate twisting of posters comments”. Really? When I’ve used copy & paste and added quotation marks”? Nice try.

You’ll be missed Crumbs - imo.

Best of luck with your investments.

And for anyone that hasn’t seen the Posters List, I’ve pasted a link below:

https://static1.squarespace.com/static/56dee71e555986fb3ae583e2/t/6508568fd9840b59e46f3597/1695045264916/Poster+list.pdf

You need to scroll to P217, P230 & P232.

Remember, LD said this:

"Showcasing the potential of our technology platforms to generate further pipeline assets with high value partnering opportunities, we will be presenting encouraging data on both the Moditope® and GlyMab® platforms. Data on antibody candidates derived from the GlyMab® platform illustrate the potential of these assets as chimeric antigen receptor T cell (CAR-T) therapies and could lead to out licensing opportunities with cell therapy companies. Furthermore, we will be presenting data bolstering the potential of Modi-2 as a solid tumour cancer therapy and further characterising the response to Moditope® peptides in preclinical studies."

Very cool :-)

Oogle - agreed.

FTSE - you didn’t explain coherently (or at all) why you remain invested here, given you openly admitted you do not believe in the company’s strategy. That a bit odd, isn’t it?

TF - did you see any response at all to your post to CW yesterday evening?

Cleaner re. your 17.17, " I was alarmed when I was told to "Back Off" thought that language only occurred followed by a threat of something more sinister ,Not scared so easily"

“Cleaner I don't remember a post to you of that kind - can you give any detail? BTW your last post, as you seem to compare your own 'heroism' to that of the Scancell team, leaves me quite uncomfortable. Are you painting white to make yourself some sort of hero here?”

Here we go again. Acquisitions are a distraction. If you believe that is true and also that you do not believe in their strategy, can you please explain coherently, why you are here??

FTSE - again hilarious.

I didn’t drive anyone off the board. I simply exposed what they transparently posted as being wrong, they were unable to accept that and chose themselves to move on (and after attempting to cover their tracks by asking for posts to be removed).

Yes, the current SP is disappointing but you seem to keep ignoring the fact that many AIM shares are in the same boat - even though their results are meeting market expectations. Can you explain why you continue to ignore this?

BOJO - nope. There are some very relevant and helpful posts, made on a regular basis.

Then there’s the irrelevant, confusing and misleading chaff that simply doesn’t help anyone ie. the road to nowhere.

What has been played out here today for all to see (160 posts and counting), is that official news released via the company, has overtaken the irrelevant links & info posted here, that take you on a road to nowhere.

Really pleasing to see. Good luck everyone.